ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES VALUE ASSESSMENT OF TRANSFORMATIVE MEDICINES IN RARE DISEASES

Published Nov 1, 2016
Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) offered a thought-provoking issue panel, Valuing Transformative Medicines in Rare Diseases: Methods and Madness, at the Society’s 19th Annual European Congress in Vienna, Austria. Paul Hodgkins, PhD, Vice President, Vertex Pharmaceuticals, Boston, MA, USA moderated the session. Panelists included:
  • Ron Akehurst, DSc, Strategic Director, BresMed Health Solutions, Sheffield, UK
  • Alastair Kent, OBE, Director, Genetic Alliance UK, London, UK
  • Maarten Postma, PhD, Professor Pharmacoeconomics, Pharmacy Department, University of Groningen, Groningen, The Netherlands
Innovative treatments for rare diseases are often transformative for patients. This is especially true if the therapy is the first to treat a disease’s underlying cause, said moderator Paul Hodgkins. It can, however, be difficult to demonstrate clinical benefit and cost effectiveness due to a number of research challenges such as small sample sizes in clinical trials and the lack of good outcome measures. The question was raised, “Why should rare and/or ultra-rare conditions be treated any differently in health technology assessment than more common conditions?” Panelists examined the pros and cons of adhering to current methods and evidence standards versus employing alternative methodological approaches and data sources in rare disease treatment evaluation. Alastair Kent, OBE discussed the importance of patient values and priorities when developing rare disease treatments and outcome measures. ISPOR offers a number of working groups and resources related to this topic, including: Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

Progress and Paradox: Healthcare Reform, Innovation, and Inequality in the Arabian Gulf and Wider Region

Apr 1, 2026

ISPOR announced the publication of a special themed section of research papers in Value in Health Regional Issues that presents a comprehensive body of evidence aimed at advancing value-based healthcare across the Arabian Gulf and the wider Middle East and North Africa region. Guest editors for the themed section are Paul Revill, Sara Al-Dallal, and Anderson Stanciole. The series was published in the March 2026 issue of Value in Health Regional Issues.

ISPOR Launches Overview of the US Healthcare System

Mar 31, 2026

ISPOR has launched a new resource that provides an overview of the healthcare system in the United States. The United States has a population of more than 300 million people and is supported by one of the most complex healthcare systems in the world. ISPOR's new website—US Healthcare System Overview—provides a summary of this intricate and highly unique healthcare system.

ISPOR’s “HEOR Explained” and “HEOR News Desk” Win Major Industry Awards

Feb 24, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced that its HEOR Explained website and videos along with its HEOR News Desk were recognized with a number of prominent industry awards from the dotCOMM, MarCom, and Viddy Awards.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×